RT Journal Article
SR Electronic
T1 Evaluating the role of common risk variation in the recurrence risk of schizophrenia in multiplex schizophrenia families
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.06.21.21259285
DO 10.1101/2021.06.21.21259285
A1 Mohammad Ahangari
A1 Amanda Elswick Gentry
A1 Tan-Hoang Nguyen
A1 Brian Verrelli
A1 Silviu-Alin Bacanu
A1 Robert Kirkpatrick
A1 Kenneth Kendler
A1 Bradley Todd Webb
A1 Brien Riley
YR 2021
UL http://medrxiv.org/content/early/2021/06/25/2021.06.21.21259285.abstract
AB Importance Multiplex schizophrenia families have higher recurrence risk of schizophrenia compared to the families of singleton cases in the population, but the source of increased familial recurrence risk is unknown. Determining the source of this observation is essential, as it will define the relative focus on common versus rare genetic variation in case-control and family studies of schizophrenia.Objective To evaluate the role of common risk variation in the recurrence risk of schizophrenia, by comparing the polygenic risk scores in familial versus ancestry matched singleton cases of schizophrenia.Design We used the latest genome-wide association study data of schizophrenia (N=166,464) to construct polygenic risk scores in multiplex family members, singleton cases and controls. To account for the high degree of relatedness in the samples, analyses were carried out using a mixed effects logistic regression model with the family structure modeled as a random effect.Setting Population and family based.Participants We used a large, homogenous sample of 1,005 individuals from 257 families from the Irish Study of High-Density Schizophrenia Families, 2,224 singleton cases and 2,284 population controls all from the population of the island of Ireland.Exposures Polygenic risk scores, diagnostic categories, familial or singleton case status.Main outcomes and measures The primary outcomes were the mixed effects logistic regression results generated from comparison between different groups.Results Polygenic risk scores in singleton cases did not differ significantly from familial cases (p=0.49), rejecting the hypothesis that an increased burden of common risk variation can account for the higher recurrence risk of schizophrenia in multiplex families.Conclusions and relevance This study suggests that a higher burden of common schizophrenia risk variation cannot account for the increased familial recurrence risk of schizophrenia in multiplex families. In the absence of elevated polygenic risk scores in multiplex schizophrenia families, segregation of rare variation in the genome and environmental exposures unique to the families may explain the increased multiplex familial recurrence risk of schizophrenia. These findings also further validate the concept of a genetically influenced psychosis spectrum in multiplex schizophrenia families as shown by a continuous increase of common risk variation burden from unaffected relatives to familial cases of schizophrenia in the families.Competing Interest StatementThe authors have declared no competing interest.Funding StatementMA, BV, S-AB, KSK, BTW and BR were supported by R01-MH114593 (to Dr. Riley). Production of GWAS data for singleton cases and controls was supported by R01-MH083094 (to Dr. Riley). Production of GWAS data for multiplex pedigrees was supported by R01-MH062276 and R01-MH068881 (to Dr. Riley). AEG was supported by T32-MH020030. T-HN was supported by NARSAD Young Investigator Grant 28599.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by Virginia Commonwealth University Office of Research Subject Protection.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesGWAS summary statistics for PGC3-SCZ GWAS is publicly available ON PGC website https://www.med.unc.edu/pgc/download-results/ GWAS summary statistics for LDL is publicly available at ENGAGE Consortium website http://diagram-consortium.org/2015_ENGAGE_1KG/. We made use of various freely available software tools in this study: PRS-CS: https://github.com/getian107/PRScs PLINK: https://www.cog-genomics.org/plink/2.0/ GMMAT: https://github.com/hanchenphd/GMMAT LDAK: http://dougspeed.com/ldak/ The custom scripts used in this study will be made publicly available upon publication.